country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-164702

Copy Link Print Information

BL-B01D1

Name: BL-B01D1
Brand: MedChemExpress
SKU: HY-164702
Price: 1450.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: Izalontamab Brengitecan; BMS 986507)

Avis client

Based on 1 Customer Validation

BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Antibody:
Izalontamab
Linker-Payload:
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
Drug-to-Antibody Ratio:
8
Conjugate Type:
Random Cysteines

Pureté : 98.59%
CAS No.: 2760528-47-8
Masse moléculaire:205830.00

Stockage:

Shipping with dry ice

-80°C, protect from light

BL-B01D1 Chemical Structure

CAS No.: 2760528-47-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Activité biologique
- Description
- IC₅₀ & Target
- In Vivo
- Essai clinique
Product Details
- Antibody
- Linker-Payload
- Drug-to-Antibody Ratio
- Conjugate Type
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]

Topoisomerase I

EGFR

HER3

Voir tous les produits spécifiques à Isoform EGFR :

Voir tous les produits spécifiques à Isoform Topoisomerase :

In Vivo

Anti-cancer

BL-B01D1 (Izalontamab Brengitecan) exhibits superior in vivo antitumor activity compared to single-target EGFR or HER3 antibody-drug conjugates in cancer-patient-derived tumor xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Product Details

Antibody

Izalontamab
Linker-Payload

Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
Drug-to-Antibody Ratio

8
Conjugate Type

Random Cysteines

Chemical Information

CAS No. 2760528-47-8
Appearance Liquid
Masse moléculaire 205830.00
Color Colorless to light yellow
SMILES

[BL-B01D1]
Synonyms

Izalontamab Brengitecan; BMS 986507
Livraison

Shipping with dry ice.
Stockage

-80°C, protect from light

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wan W, et al. Abstract 2642: BL‑B01D1, a novel EGFR×HER3‑targeting ADC, demonstrates robust anti‑tumor efficacy in preclinical evaluation. Cancer Research. 2023 Apr 4;83(7_Supplement):2642.

[2]. Liu C, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025 Oct;31(10):3485-3491.

[3]. Ma Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024 Jul;25(7):901-911. [Content Brief]

[4]. Bian X, et al. Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Nov 10;43(32):3505-3515.

[5]. Zhang L, et al. BL‑B01D1, a first‑in‑class EGFR×HER3 bispecific antibody‑drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first‑in‑human phase 1 study. Journal of Clinical Oncology. 2023 Jun;41(16_suppl):3001.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- IC₅₀ & Target
- In Vivo
- Essai clinique
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

BL-B01D1

Voir tous les produits spécifiques à Isoform EGFR

Voir tous les produits spécifiques à Isoform Topoisomerase